Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
June 03 2022 - 12:30PM
Esperion (NASDAQ: ESPR) announced findings from a real-world
analysis of more than 400,000 patients at high-risk for
atherosclerotic cardiovascular disease (ASCVD). The findings were
presented at the National Lipid Association Scientific Sessions in
Scottsdale, Arizona.
“While professional guidelines are clear on
defining appropriate lipid-lowering therapies for individuals at
high-risk for ASCVD based on LDL-cholesterol, this analysis
demonstrates major shortfalls in the real-world application of
those guidelines,” said JoAnne Foody, MD, FACC, FAHA, chief medical
officer of Esperion. “While LDL-cholesterol as a cardiovascular
risk factor is well known, there remains a persistent gap in
applying evidence-based therapies to reduce LDL-C. These data
reinforce the urgent need to improve the use of all appropriate
statin and non-statin lipid-lowering therapies among at-risk
patients.”
The analysis examined deidentified electronic
health records from approximately 90 US health systems between 2017
and 2018. Three populations of high-risk individuals for ASCVD
disease for primary prevention were included in the study: 1)
patients with diabetes mellitus aged 40-75, 2) patients with
calculated 10-year ASCVD risk ≥7.5% and age 40-75 and 3)
individuals with LDL-C ≥190 mg/dL or familial hypercholesterolemia
based on diagnosis code. Medication data, including self-reported
use of supplements, were also examined. Patients were classified
as: on appropriate-intensity statin (at least moderate intensity if
diabetes mellitus or high 10-year ASCVD risk [≥7.5%], and at least
high-intensity if LDL-C≥190mg/dL), on under-dosed statin, or not on
a statin based on the 2013 ACC/AHA Cholesterol Guidelines in effect
during the study time period.
The analysis identified 412,913 patients
recommended for lipid-lowering therapy. Overall, 6.6% were on
under-dosed statin, and 46.9% were not on any statin. Utilization
of non-statin lipid-lowering therapy (ezetimibe, fibrates, niacin,
bile acid sequestrants, and PCSK9 inhibitors) was low overall
across all three groups (8.1%). However, nearly one in ten (9.3%)
of those recommended for primary prevention reported taking
non-prescription Omega-3/fish oil supplements.
“What was striking about this analysis is that
not only are nearly half of adults not receiving any statin at all,
but individuals also reported using supplements like fish oil with
close to the same frequency of non-statin lipid-lowering
therapies,” said Kristin Gillard, PharmD, PhD, Health Economics and
Outcomes Research lead at Esperion. “This is an important notice to
healthcare professionals about the need for greater education and
awareness of FDA-approved, non-statin lipid-lowering
therapeutics.”
Esperion TherapeuticsEsperion
works hard to make our medicines easy to get, easy to take and easy
to have. We discover, develop and commercialize innovative
medicines and combinations to lower cholesterol, especially for
patients whose needs aren’t being met by the status quo. Our
entrepreneurial team of industry leaders is inclusive, passionate
and resourceful. We are singularly focused on managing cholesterol
so you can improve your health easily. For more information, please
visit www.esperion.com and follow us on Twitter at
www.twitter.com/EsperionInc.
Forward-Looking StatementsThis
press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities
laws, including statements regarding future operations, commercial
products, clinical development, and other statements containing the
words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Forward-looking
statements involve risks and uncertainties that could cause
Esperion’s actual results to differ significantly from those
projected, including, without limitation, the impact of the ongoing
COVID-19 pandemic on our business, revenues, results of operations
and financial condition, the net sales, profitability, and growth
of Esperion’s commercial products, clinical activities and results,
supply chain, commercial development and launch plans, and the
risks detailed in Esperion’s filings with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Esperion
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
Contact:Corporate
Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024